Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB.

J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21.

2.

Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models.

Ploquin A, Olmos D, Ferté C, Cassier PA, Kramar A, Duhamel A, Penel N.

Crit Rev Oncol Hematol. 2012 Aug;83(2):242-8. doi: 10.1016/j.critrevonc.2011.11.008. Epub 2012 Jan 9. Review.

PMID:
22226569
3.

Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.

Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI.

Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803. Review.

PMID:
10098435
4.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
5.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
6.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

Items per page

Supplemental Content

Write to the Help Desk